Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous iPS-NSC for Parkinson's Disease
NCT03815071Phase 1Unknown
- Sponsor
- Allife Medical Science and Technology
- Start
- Feb 2019
- Primary completion
- Feb 2020
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
01
Overview
Phase 1, open-label, single-arm trial of iPS-NSC in Parkinson's disease (PD), sponsored by Allife Medical Science and Technology. Primary endpoint: Occurrence of treatment related adverse events at 1 year. Status: unknown.
02
Drugs
iPS-NSC
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03815071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815071.